2021
Case Report: Wound Closure Acceleration in a Patient With Toxic Epidermal Necrolysis Using a Lyophilised Amniotic Membrane
LIPOVÝ, Břetislav, Martin HLADÍK, Petr ŠTOURAČ a Serhij FOROSTYAKZákladní údaje
Originální název
Case Report: Wound Closure Acceleration in a Patient With Toxic Epidermal Necrolysis Using a Lyophilised Amniotic Membrane
Autoři
LIPOVÝ, Břetislav (203 Česká republika, domácí), Martin HLADÍK (703 Slovensko, domácí), Petr ŠTOURAČ (203 Česká republika, domácí) a Serhij FOROSTYAK (203 Česká republika, garant, domácí)
Vydání
Frontiers in bioengineering and biotechnology, Laussane, Frontiers Media S.A. 2021, 2296-4185
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30401 Health-related biotechnology
Stát vydavatele
Švýcarsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 6.064
Kód RIV
RIV/00216224:14110/21:00121942
Organizační jednotka
Lékařská fakulta
UT WoS
000645548500001
Klíčová slova anglicky
toxic epidermal necrolysis; lyophilised amniotic membrane; reepithelization; infection control; toxic epidermal necrolysis; amniotic membrane
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 19. 7. 2021 09:14, Mgr. Tereza Miškechová
Anotace
V originále
Background: Toxic epidermal necrolysis (TEN) is a rare life-threatening disease that mainly affects the skin and mucous membranes, resulting from a toxic delayed-type hypersensitivity (DTH) reaction (type IV reaction) to the presence of foreign antigens such as drugs. The clinical symptoms are caused by pathophysiological processes leading to massive apoptosis of keratinocytes in the dermo-epidermal junction. This results in the formation of a bulla and subsequent separation of the entire epidermis with the exposure of the dermis. The current approach in the local therapy of TEN prefers the use of biological dressings, which helps provide several critical requirements for defect healing; in particular, it helps in the acceleration of the spontaneous wound closure (re-epithelialization) of the skin defect and the reduction of the risk of development of various complications and infections, such as the risk of pathological scar maturation. This paper is a case report of the use of a lyophilized amniotic membrane (AM) for accelerating wound healing in a patient with TEN. Case Presentation: We report a case of an 8-year-old girl transferred to our center with a histologically confirmed diagnosis of TEN. Despite the application of immunosuppressive therapy consisting of corticosteroids and intravenous immunoglobulins, we have observed disease progression and exfoliation of up to 60% of the total body surface area (TBSA). In the facial area, which is cosmetically privileged, we decided to use the lyophilized amniotic membrane (Amnioderm (R)) to cover up approximately 2% of the TBSA. Within 2 days after the application, we observed accelerated reepithelialisation, with rapid wound closure. We have not observed any side effects nor infections during the subsequent phases of wound healing. Skin defects in non-facial areas of the body were treated with synthetic dressings. When compared to the areas covered with the lyophilized AM, the healing process was prolonged. Conclusions: To our knowledge, this is the first case study using a lyophilized amniotic membrane in the treatment of a patient with TEN. The AM application in the cosmetically-privileged area (face), proved to be very efficient in the treatment of TEN patients. The use of this allogeneic material demonstrated excellent biocompatibility and caused a unique acceleration of epithelialization and wound healing, yielding also excellent long-term results. The current study opens broad possibilities for clinical application of the used material, the improvement of current therapy of patients with TEN and better outcomes and recovery of patients.